Forecast
| Buy |
Â
3 |
| Hold |
Â
1 |
| Sell |
Â
0 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Zealand Pharma: Petrelintide reaches primary endpoint in phase-2 study
Zealand Pharma reports that Petrelintide met the primary endpoint in the phase-2 study Zupreme-2. Weekly subcutaneous injections resulted in a statistically significant and clinically meaningful weight loss versus placebo in all three treatment groups after 28 weeks. Together with Roche, Zealand is initiating a phase-3a program consisting of Zupreme-3, Zupreme-4 and Zupreme-5. » More on finanzen.net
Zealand Pharma sells Rusfertide royalties to Royalty Pharma for $100 million
Zealand Pharma has sold its economic rights to Rusfertide to Royalty Pharma for $100 million. The payment is made in two tranches: $50 million at closing and $50 million on the first anniversary; the transaction is complete. Zealand retains a residual royalty of 0.25% on annual worldwide net sales above $1.5 billion, and Royalty Pharma receives 0.75% above that threshold. The FDA has set a target date for the approval application in the third quarter of 2026, and Takeda will take over worldwide commercialization. » More on de.investing.com
Jefferies downgrade pushes Zealand Pharma shares lower
Jefferies downgraded Zealand Pharma from "Buy" to "Hold" and cut the price target from 505 DKK to 320 DKK, a decline of about 37%. The analyst house cited a lack of near‑term catalysts and reduced the success probability for survodutide from 60% to 40% due to ongoing tolerability concerns after Phase III data. With no company‑specific news, the downgrade was the main driver of the share drop; a short‑term recovery now depends largely on progress with petrelintide. » More on de.investing.com
Zealand Pharma recovers after stock slump over study data
Zealand Pharma's shares rose about 6.8% today, partially reversing a more than 24% decline after negative study results. The Phase‑III trial of Survodutid showed high discontinuation rates due to gastrointestinal side effects, and Phase‑II data for Petrelintid showed only around 9% placebo‑adjusted weight loss, prompting Barclays to voice safety concerns. The stabilization today is attributed to the announced appearance of the CEO at the Goldman Sachs conference and an ongoing share buyback program (up to DKK 1.3bn). A fundamental turnaround in the clinical outlook is not signaled; the stock remains well below its 52‑week high. » More on de.investing.com
Zealand Pharma shares plunge after mixed survodutide data from Boehringer
Boehringer Ingelheim published phase‑III data on survodutide showing strong weight loss and substantial reduction of liver fat, but high discontinuation rates due to side effects. As Boehringer’s partner, Zealand Pharma lost up to about 25% in Copenhagen at one point, wiping out roughly $900 million in market value. Boehringer sees medical potential but plans further studies with more flexible dosing; in the highest‑dose group nearly a quarter of patients discontinued treatment, with an overall discontinuation rate of 19% versus 2.9% in the placebo group. Experts highlight opportunities particularly for MASLD patients, while the market for obesity drugs is expected to be very large by 2030/the 2030s. » More on n-tv.de
Financials
In the last quarter, Zealand Pharma Aktie had revenue of €535.08K and net profit of -€7.22M
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 535.08K | 91.94% |
| Gross profit | 535.08K | 90.57% |
| Net profit | -7.22M | 86.66% |
| EBITDA | 2.27M | 104.82% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €1.89B |
Number of shares | 66.33M |
52-week high/low | €74.35 - €28.44 |
| Dividends | No |
Beta | 0.61 |
P/E ratio | 4.84 |
PEG ratio | -0.09 |
P/B ratio | 0.87 |
P/S ratio | 3.07 |
Company profile
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
| Name | Zealand Pharma Aktie |
| CEO | Adam Sinding Steensberg |
| Headquarters | Søborg,
Denmark |
| Website | |
| Sector | Health Care |
| Industry | Biotechnology |
| IPO | 11/23/2010 |
| Employees | 605 |
Ticker symbols
| Exchange | Symbol |
|---|---|
Pnk | ZLDPF |
Nasdaq Copenhagen | ZEAL.CO |
Copenhagen | ZEAL.CO |
Frankfurt | 22Z.F |
DĂĽsseldorf | 22Z.DU |
London | 0NZU.L |
MĂĽnchen | 22Z.MU |
SIX | ZEAL.SW |